---
title: "Ipilimumab plus Nivolumab Yields 50% Observed ORR in Small WD‑NET Phase II Cohort"
id: "frontiers-in-immunology-4-dual-immune-checkpoint-blockade-in-advanced-well-differentiated-neuroendocrine"
canonical_url: "https://medichelpline.com/clinical-feed/frontiers-in-immunology-4-dual-immune-checkpoint-blockade-in-advanced-well-differentiated-neuroendocrine"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "Frontiers in Immunology"
source_url: "https://www.frontiersin.org/articles/10.3389/fimmu.2026.1824034"
published_at: "2026-11-13T00:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Ipilimumab plus Nivolumab Yields 50% Observed ORR in Small WD‑NET Phase II Cohort
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/frontiers-in-immunology-4-dual-immune-checkpoint-blockade-in-advanced-well-differentiated-neuroendocrine
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** Frontiers in Immunology
- **Source URL:** [Original Journal Publication](https://www.frontiersin.org/articles/10.3389/fimmu.2026.1824034)
- **Published At:** 2026-11-13T00:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- A single-center phase II trial tested combined **ipilimumab** and **nivolumab** in advanced, well‑differentiated neuroendocrine tumors (WD‑NET) after progression on prior therapies. - Planned design used Simon’s two‑stage approach, with a primary endpoint of objective response rate (**ORR**) by RECIST v1.1 and a pre-specified threshold of interest >15%. - Treatment regimen reported in the source: ipilimumab 1 mg/kg every 6 weeks and nivolumab 240 mg every 2 weeks, for up to 2 years. - Nine patients were enrolled before early closure (6 lung, 2 pancreatic, 1 small bowel); mean age 63.7 years. - Of eight evaluable patients, four achieved a confirmed radiologic response; the observed **ORR** among evaluable patients was 50% (95% CI: 16–84). - Five of nine patients experienced immune‑related adverse events; detailed toxicity grading and individual event lists appear in the source tables. - Correlative analyses used IHC for CD3, CD20, CD8, PD‑1, and PD‑L1 on FFPE tissue; investigators reported higher pre‑treatment **CD3** infiltration in tumors from radiologic responders versus nonresponders. - The study closed before completing Stage 1 accrual (9 of 20 planned for Stage 1; 56 planned overall per protocol), so the authors stated no formal statistical conclusion could be drawn. - Trial registration provided: ClinicalTrials.gov identifier NCT03420521. - The source did not report additional efficacy endpoints such as median PFS or OS for this cohort, nor did it provide full toxicity grade distributions in the text excerpt; those details are presented in the article tables per the source.
## Clinical Analysis & Structured Key Points
Frontiers | Dual immune checkpoint blockade in advanced well-differentiated neuroendocrine tumors, a phase II clinical trial 15%.ResultsNine patients were enrolled (6 lung, 2 pancreatic, and 1 small bowel). The Mean age was 63.7 years. Four of eight evaluable patients achieved confirmed response (ORR 50%, 95% CI: 16–84). Five of nine patients experienced immune-related toxicity. The trial closed before completing Stage 1 enrollment (9 of 20 planned patients). No formal statistical conclusion could be applied given the incomplete accrual. We observed a higher CD3 infiltration in pre-treatment tumors of patients who had achieved radiological response as compared with those of nonresponders.ConclusionsThe combination of ipilimumab and nivolumab in patients with WD-NET results in an observed ORR of 50% in this small clinical trial. These results are hypothesis-generating given the small sample size and premature trial closure.Clinical trial registrationhttps://clinicaltrials.gov/study/NCT03420521, identifier NCT03420521"> CLINICAL TRIAL article Front. Immunol. , 13 November 2026 Sec. Cancer Immunity and Immunotherapy Volume 17 - 2026 | https://doi.org/10.3389/fimmu.2026.1824034 Published in Frontiers in Immunology Cancer Immunity and Immunotherapy 7 impact factor 11.3 citescore Part of a Research Topic Cancer Immunotherapy and Tumor Escape Mechanisms: New Insights and Future Directions 54k views 17 articles Editor & Reviewers Edited by M K MOUMITA KUNDU Reviewed by Y X Yingkun Xu C G Carsten Grötzinger Outline Figures and Tables Figure 1 View in article Figure 2 View in article Figure 3 View in article Table 1 Baseline demographic and clinicopathologic disease characteristics. View in article Table 2 Overall response rate. View in article Table 3 Immune-related adverse events and relation to patient characteristics and responses. View in article Table 4 Immune-related adverse events. View in article Table 5 Serious adverse events (requiring reporting and/or hospital admission). View in article CLINICAL TRIAL article Front. Immunol. , 13 November 2026 Sec. Cancer Immunity and Immunotherapy Volume 17 - 2026 | https://doi.org/10.3389/fimmu.2026.1824034 Dual immune checkpoint blockade in advanced well-differentiated neuroendocrine tumors, a phase II clinical trial A D Ana De Jesus-Acosta 1,2,3,4,5 * Q Z Qingfeng Zhu 6 C H Chen Hu 7 S K Suqi Ke 7 R A Robert A. Anders 6 S C Susan Combs Scott 1 B P Benjamin Philip Levy 1 V A Valsamo Anagnostou 1 J R Julie R. Brahmer 1 P B Peter Bela Illei 6 E M Elizabeth M. Jaffee 1,2,3,4,5 K M Kristen Marrone 1 P M Patrick M. Forde 1 +5 more C L Christine L. Hann 1 * 1. The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, United States 2. The Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins University School of Medicine, Baltimore, MD, United States 3. The Cancer Convergence Institute at Johns Hopkins University School of Medicine, Baltimore, MD, United States 4. The Pancreatic Cancer Precision Medicine Center of Excellence Program at Johns Hopkins University School of Medicine, Baltimore, MD, United States 5. The Skip Viragh Pancreatic Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, United States 6. Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, United States 7. Division of Biostatistics and Bioinformatics, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, United States See more Article metrics View details https://clinicaltrials.gov/study/NCT03420521 https://clinicaltrials.gov/study/NCT03420521 , identifier NCT03420521 Abstract Background: Limited options result in objective responses in patients with well-differentiated neuroendocrine tumors (WD-NET). We tested the efficacy of dual immune checkpoint blockade in patients with WD-NET. Methods: We planned a phase II clinical trial in patients with WD-NET who progressed within the past 12 months to standard treatments. Patients received ipilimumab 1 mg/kg every 6 weeks and nivolumab 240 mg every 2 weeks for up to 2 years. The primary endpoint was objective response rate (ORR) by RECIST v1.1. Using Simon’s 2-stage design, the study planned to accrue 56 patients. This regimen would be considered promising if ORR >15%. Results: Nine patients were enrolled (6 lung, 2 pancreatic, and 1 small bowel). The Mean age was 63.7 years. Four of eight evaluable patients achieved confirmed response (ORR 50%, 95% CI: 16–84). Five of nine patients experienced immune-related toxicity. The trial closed before completing Stage 1 enrollment (9 of 20 planned patients). No formal statistical conclusion could be applied given the incomplete accrual. We observed a higher CD3 infiltration in pre-treatment tumors of patients who had achieved radiological response as compared with those of nonresponders. Conclusions: The combination of ipilimumab and nivolumab in patients with WD-NET results in an observed ORR of 50% in this small clinical trial. These results are hypothesis-generating given the small sample size and premature trial closure. Clinical trial registration: https://clinicaltrials.gov/study/NCT03420521 , identifier NCT03420521 Introduction Neuroendocrine tumors (NETs) are a heterogeneous group of malignancies originating in neuroendocrine cells throughout the body. Although historically considered a rare disease, the incidence and prevalence of NETs have significantly increased over the past few decades, raising the importance of further research ( 1 , 2 ). Well-differentiated (WD) NETs most commonly arise in the gastrointestinal (GI) tract, pancreas, and lung ( 3 ). For patients with advanced disease, systemic therapy with somatostatin analogs represents a foundational therapy, both for symptom control and disease stability ( 4 , 5 ). Additional available therapies include the mTOR inhibitor, everolimus, tyrosine kinase inhibitors such as sunitinib and cabozantinib, and peptide receptor radionuclide therapy ( 6 – 10 ). Despite these advances, durable objective responses remain infrequent. Immunotherapy with immune checkpoint inhibitors (ICIs) has revolutionized the field of oncology with increased responses and survival in many cancer types. The role of ICIs in well-differentiated NETs, however, remains undefined. Initial studies analyzing tissue specimens in patients with gastroenteropancreatic NETs (GEP-NETs) noted programmed death-ligand 1 (PD-L1) expression ranging from 0% to 21% ( 11 ). Further, PD-L1 expression correlated with higher grade and was associated with worse survival ( 12 ). Among 168 pulmonary NET specimens, applying a TPS ≥1% threshold for PD-L1 positivity, 7% of typical carcinoids were PD-L1–positive, whereas no atypical carcinoid samples demonstrated PD-L1 expression ( 13 ). Clinical trials testing single-agent PD-1 or PD-L1 inhibitors in advanced NETs, including lung, GI, and pancreatic, reported objective response rates (ORRs) of 3%–12%, suggesting a limited single-agent activity in these tumors ( 14 , 15 ). In addition to relatively low PD-L1 expression, WD-NET exhibits features that could contribute to this lack of responsiveness to single agent ICI, such as low tumor mutational burden ( 16 ) and lack of T-cell infiltration ( 17 ). Other mechanisms of resistance include the presence of cancer-associated fibroblasts expressing tryptophan 2,3-dioxygenase and creating a suppressive stromal barrier ( 18 ), low IFNγ-inducible gene expression ( 19 ), and the abundance of immunosuppressive myeloid cells with high expression of CD47 and CD74, which are important contributors to ICI resistance ( 19 ). Collectively, these features are thought to impair antigenicity, T-cell recruitment, and checkpoint-mediated immune activation, thereby limiting the efficacy of PD-1/PD-L1 monotherapy and providing rationale for using combination strategies. In other cancer types, combination dual checkpoint blockade using anti-PD1 and anti-CTLA-4 agents has shown enhanced and durable responses leading to improved survival when combining these agents in melanoma, renal cell carcinoma, mesothelioma, and hepatocellular carcinoma ( 20 – 22 ). In the field of GEP-NETs, higher grade tumors, WD-NET and poorly differentiated neuroendocrine carcinomas (NECs) show higher response rates to dual checkpoint blockade (ORR 15%–24%) compared to well-differentiated NETs (ORR 6%–10%) ( 23 – 26 ). High-grade NENs have higher TMB and increased PD-1/PD-L1 expression. CA209–538 trial, which specifically evaluated nivolumab plus ipilimumab in advanced NETs and showed an ORR of 24% with a clinical benefit rate of 72%, a median PFS of 4.8 months, and a median OS of 14.8 months. Notably, 43% of patients with pancreatic NENs and 33% with atypical bronchial carcinoid achieved objective responses ( 23 ). Additionally, the SWOG S1609 DART trial demonstrated similar activity in high-grade NENs ( 32 ). Real-world data have shown dual checkpoint blockade with nivolumab plus ipilimumab has superior outcomes compared to single-agent ICI or chemotherapy in the second-line setting for extrapulmonary NECs, with improved median PFS (258 days vs. 56.5 days vs. 47 days) and OS ( 24 , 27 ). The NCCN guidelines (2025) now include nivolumab plus ipilimumab as a category 2B option for well-differentiated grade 3 NETs with unfavorable biology and for poorly differentiated NECs after progression on chemotherapy, supporting the investigation of this combination in NETs. The limited responses in patients using single-agent immunotherapy in patients with NENs and the higher responses using combination therapies across multiple tumor sites provided rationale for the combination. In this study, we aimed to evaluate the efficacy of dual checkpoint blockade in patients with NETs of GI and lung origin using the anti-PD1 agent, nivolumab, combined with the anti-CTLA-4 antibody, ipilimumab. We included correlative studies to evaluate immune system activation and for potential biomarker identification. Methods Study design We planned a single-center, open-label, phase 2 study to evaluate the ORR of the combination of nivolumab and ipilimumab in advanced, well-differentiated neuroendocrine tumors. The study took place in Johns Hopkins Hospital, Baltimore, Maryland. The study protocol was approved by the Johns Hopkins institutional review board. All participating patients signed informed consent prior to study-related procedures. Patients Eligible patients had histologically confirmed advanced, progressive, well-differentiated NET of the pancreas, GI tract, or lung. Patients with pancreas or GI tumors included well-differentiated low grade (G1) or intermediate grade (G2) per 2017 World Health Organization (WHO) classification ( 28 ). Patients with lung NETs included low grade (typical carcinoid) and intermediate grade (atypical carcinoid) based on the 2015 WHO classification ( 29 ). The terms “typical” and “atypical” are still used to describe low- versus intermediate-grade tumors arising in the lung, and the mitotic rate (rather than Ki-67 index) and the presence of necrosis are the primary determinants of grade. Patients had measurable disease per RECIST 1.1 criteria and documented progression within 12 months prior to enrollment. Patients with lung NETs must have progressed after at least one line of therapy, and patients with GI NETs must have had at least two lines of prior therapy. Participating patients were >18 years of age and Eastern Cooperative Oncology Group performance status ≤1. Patients had normal organ and marrow function. Liver function requirements included AST/ALT ≤3 × institutional ULN (≤5 × ULN in the presence of liver metastases), bilirubin ≤1.5 × institutional ULN, and creatinine clearance (CrCl) ≥40 ml/min. Patients with autoimmune diseases or conditions requiring systemic corticosteroids at a dose > 10 mg daily prednisone equivalent or immunosuppressive medications were excluded. Patients with other active malignancies requiring concurrent intervention were excluded. For correlative studies, archival or new core biopsies pretreatment were required for participation. Outcomes The primary endpoint was the ORR of patients with advanced GI, pancreatic, or lung NET treated with nivolumab plus ipilimumab. Secondary endpoints included safety and tolerability of the combination, progression-free survival (PFS) at 6 months, 12, and 24 months, disease control rate (DCR), duration of response (DOR), and overall survival (OS). Exploratory objectives using correlative tissue biopsies included immunohistochemistry (IHC) staining for CD20/CD3 and PD-L1. Treatment administration Patients received nivolumab 240 mg every 2 weeks and ipilimumab 1 mg/kg every 6 weeks; both agents could be continued for up to 2 years. Therapy was discontinued in the case of confirmed disease progression, unacceptable toxicity, intercurrent illness that prevented continuation of therapy, non-compliance, or the patient’s request to withdraw from treatment. Treatment beyond initial investigator-assessed RECIST 1.1-defined progression was permitted if patients were deriving clinical benefit and without rapid disease progression, adequate tolerance of study treatment, and stable performance status. A follow-up confirmatory scan was performed within six weeks of the original PD. For the patients who continued study therapy beyond progression, further progression was defined as an additional 10% increase in tumor burden from the time of initial PD. Nivolumab and ipilimumab treatment were discontinued upon documentation of further progression. Subjects who discontinue treatment for reasons other than disease progression continued to have tumor assessments until progression was confirmed radiographically. Toxicities were monitored and graded using the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. Subjects were followed for drug-related toxicities until these toxicities resolved, returned to baseline, or were deemed irreversible. Subjects that had drug-related toxicities that met criteria for dose delay had both drugs (ipilimumab and nivolumab) delayed until retreatment criteria were met. Treatment was discontinued if delays in dosing lasted >12 weeks from ipilimumab dosing OR >6 weeks from nivolumab dosing. Correlative studies For correlative studies, archival or recently collected formalin-fixed, paraffin-embedded (FFPE) tumors were allowed. An FFPE tumor tissue block or 10 unstained slides of the tumor sample were obtained. IHC was used to assess the number and composition of immune infiltrates to define the immune cell subsets present within FFPE tumor tissue. IHC analyses included markers CD20/CD3 and PD-L1. Staining for CD20/CD3: Automated dual staining was performed on the Leica Bond RX (Leica Biosystems, Buffalo Grove, IL). Slides were baked and dewaxed, followed by low pH sodium citrate buffer antigen retrieval for 20 min at 100 °C. Endogenous peroxidase was blocked using Peroxidase Block (Refine Kit), and then anti-CD20 clone L26 (CD20-L226-L-CE, Leica Biosystems) was applied for 15 min at a concentration of 0.19 µg/ml at room temperature using Antibody Diluent (S302283-2, Agilent Technologies Inc.). Detection was performed using the Bond Polymer Refine Kit (DS9800, Leica Biosystems). A second round of low pH sodium citrate buffer antigen retrieval for 20 min at 95 °C was performed. Anti-CD3 clone LN10 (CD3-565-L-CE, Leica Biosystems) was applied for 30 min at a concentration of 0.213 µg/ml using Antibody Diluent. Detection was performed using the Bond Polymer Red Refine Kit (DS9390, Leica Biosystems). Slides were counterstained, dried, and coverslipped using Ecomount (5082832, Biocare Medical, Walnut Creek, CA). Quantification was performed by a pathologist blinded to clinical outcomes. Markers were not quantified in high-power fields. For PD-L1 quantification, the percentage of PD-L1 membranous expression was manually counted in tumor, stroma, and invasive front (RAA and FB). For other markers (CD3, CD8, CD20), slides were scanned at 20× objective equivalent (0.49 microns/pixel) with a Hamamatsu NanoZoomer XR slide scanner. Each image was annotated for regions of tumor, invasive front (400-micron area toward the center of the tumor and 400-micron area outside the tumor edge), and non-tumor regions by the study pathologist (RAA). Positive signals were reported as cell density per mm 2 tissue area (CD3, CD8, CD20, and PD-1) or percentage-stained surface area of total annotated area by digital analysis (Halo, Indica Labs, Albuquerque, NM). PD-L1 automated protocol: Automated PD-L1 staining was performed on the Leica Bond RX (Leica Biosystems, Buffalo Grove, IL). Slides were baked online for 30 min at 60 °C with paraffin removal using Dewax (AR9222, Leica) at 72 °C. Antigen retrieval was performed using high pH EDTA buffer (AR9640, Leica) at 100 °C for 40 min and low pH sodium citrate buffer (AR9961, Leica) at 95 °C for 40 min. Endogenous peroxidase was blocked using BLOXALL (SP-6000-100, Vector Laboratories, Inc., Newark, CA) for 10 min, followed by blocking for non-specific binding using Protein Block (X090930, Agilent Technologies, Santa Clara, CA) for 15 min. Anti-PD-L1 clone SP142 (ab228462, Abcam plc., Cambridge, MA) was applied for 180 min at 0.1 µg/ml in Antibody Diluent (S302283-2, Agilent Technologies Inc., Santa Clara, CA). Detection was performed by applying 25% PowerVision Poly-HRP anti-Rabbit IgG (PV6119, Leica) diluted in 1× TBS in diH 2 O (351-086-101, Quality Biological, Gaithersburg, MD) for 10 min, followed by TSA Plus DIG (NEL748001KT, Akoya Biosciences, Marlborough, MA) diluted 1:450 in 1 × Plus Amplification Diluent (FP1498, Akoya). Mouse anti-Digoxigenin-HRP (200-032-156, The Jackson Laboratory, Bar Harbor, ME) was applied for 30 min, diluted 1:100 in 1 × Antibody Diluent/Block (ARD1001EA, Akoya). Visualization was performed using HighDef DAB (ENZ-ACC105-0200, Enzo Life Sciences Inc., Farmingdale, NY) for 2.5 min and counterstained using 10% Hematoxylin (GHS316-500ML, Millipore Sigma, St. Louis, MO) in diH 2 O for 1 min. Slides were dried at room temperature and coverslipped using Ecomount (5082832, Biocare Medical, Walnut Creek, CA). PD-L1 condensed protocol: Automated PD-L1 staining was performed on the Leica Bond RX (Leica Biosystems). Slides were baked and dewaxed online, followed by antigen retrieval. Endogenous peroxidase was blocked, and then the anti-PD-L1 clone SP142 (ab228462, Abcam) was applied for 180 min at a concentration of 0.1 µg/ml at room temperature. Detection was performed by combining the PowerVision (Leica) and Tyramide Signal Amplification (Akoya) systems. Slides were counterstained, dried, and coverslipped using Ecomount (Biocare Medical). Statistical considerations The primary objective was to determine the ORR per RECIST 1.1 criteria of advanced, progressive, well-differentiated nonfunctional NET of the lung, pancreas, or GI tract treated with nivolumab plus ipilimumab. ORR was defined as the number of subjects with a best overall response (BOR) of confirmed complete response (CR) or partial response (PR), divided by the number of treated subjects who have at least one RECIST scan. Tumor response was assessed according to RECIST v1.1. All imaging was reviewed prospectively by a RECIST-certified radiologist who was not involved in the clinical care of participants; the treating investigators did not adjudicate the primary response endpoint. Objective responses (CR or PR) required confirmation on a subsequent scan obtained no fewer than 4 weeks after the criteria for response were first met, in accordance with RECIST v1.1. ORR was calculated with exact 95% binomial confidence intervals. The secondary objectives were to assess the safety and tolerability of nivolumab plus ipilimumab. All patients who received at least one dose of niv
## Related Clinical Research

- [Sintilimab plus R-CHOP vs DA-EPOCH-R in PMBCL — article content unavailable on source page](https://medichelpline.com/clinical-feed/frontiers-in-immunology-15-sintilimab-plus-r-chop-versus-da-epoch-r-as-first-line-therapy-for-primary.md)
- [VE800 Plus Nivolumab Phase 1 (CONSORTiUM-IO) in Select Refractory or Metastatic Cancers](https://medichelpline.com/clinical-feed/medrxiv-13-consortium-io-a-phase-1-study-evaluating-ve800-plus-nivolumab-in-treatment-of.md)
- [Amsokigene autoleucel TIL Therapy Shows Promise in ICI-Resistant Advanced Melanoma Trials](https://medichelpline.com/clinical-feed/nature-1-regulatable-membrane-bound-il-15-engineered-til-cell-therapy-for-immune.md)
- [Corticosteroid-refractory checkpoint inhibitor pneumonitis in lung cancer: heterogeneity and mecha](https://medichelpline.com/clinical-feed/frontiers-in-immunology-11-corticosteroid-refractory-checkpoint-inhibitor-pneumonitis-in-lung-cancer.md)
- [Dual immune checkpoint inhibition for melanoma brain metastases: safety and efficacy meta-analysis](https://medichelpline.com/clinical-feed/pubmed-42934318.md) (DOI: 10.1007/s10143-026-04538-w)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.